by
Ed Sharpe
What’s the
best way to take mineral supplements? Picolinates? Amino
acid chelates? Chelates involving other organic acids such
as citrates? Whenever anyone asks my opinion on such matters,
I find myself giving an answer they often don’t expect: “Try
orotates!” The blank looks I usually get in response
tell me that most people need some educating on the subject,
hence this article.
Orotates are the
mineral salts of orotic acid, a natural substance found
in our bodies and also in various foods including dairy
products. As theorized many years ago by the pioneering
German physician Hans Nieper, orotates are a component
of a natural system of electrolyte carriers for distributing
minerals throughout the body. 1 (A
different compartment of this same system uses amino acid
complexes such as aspartates and arginates to deliver minerals.)
Based on his observations of cells in culture, Nieper concluded
that molecules of calcium orotate and magnesium orotate
can pass through cell membranes intact without “dissociating” or
breaking apart into their component ions, and thereafter
release their respective ions only at specific membrane
sites within the cell. 2 Subsequently
he extended this principle to include other orotates such
as lithium and zinc.
Working at his
clinic in Hannover, Germany, Nieper applied his unique
discoveries to the treatment of diseases such as cancer,
heart disease, multiple sclerosis, and rheumatoid arthritis
as well as other autoimmune conditions. Over the course
of more than four decades Dr. Nieper treated thousands
of patients with his innovative mineral transporters, many
apparently with great success. However, in later years
he published relatively little in medical journals, preferring
instead to reserve his time for treating patients and for
presenting occasional seminars about his work to medical
professionals and consumers. As a result, his discoveries
have been considered controversial by mainstream medicine
or simply ignored, at least until recently.
Hans Nieper died
in October, 1998 at the age of 70—ironically just
at a time when many of his ideas had finally begun gaining
wider acceptance. Only a few weeks before his death, in
fact, the collected papers from a symposium on the medical
uses of magnesium orotate were published in the journal
Cardiovascular Drugs and Therapy. Overall, the symposium
lent credence to Nieper’s claims for the cardiovascular
benefits of magnesium orotate while calling for additional
human trials. 3
How do the orotates work?
That’s a
complex question necessitating a somewhat detailed discussion
of biochemistry and for this reason my explanation has
been relegated to an article of its own. See How Orotates
Work. For now I’ll just state my summary conclusions:
There is independent scientific evidence corroborating
Nieper’s theory of orotates as mineral transporters.
In my judgment, the evidence tends to support Nieper’s
criteria for orotate as an electrolyte carrier, namely,
(1) a low dissociation constant, (2) an affinity for specific
cellular systems or organs, and (3) a metabolic pathway
which liberates the transported mineral within the targeted
organ or system. 1
Perhaps the recent
wave of interest in Dr. Nieper’s compounds will inspire
further research on the mechanism of transport. Until then
there’s plenty of evidence for the validity of Dr.
Nieper’s ideas in previous publications by Nieper
and other researchers. The following sections summarize
these results on the medical and biological effects of
the various mineral orotates, together with a brief discussion
of other potential uses. Beyond that, there is direct and
compelling evidence from personal experience—see
my article Orotates for Weight Loss, Cognitive Enhancement,
and Athletic Performance for details. To give but one example,
there can be little doubt about the effectiveness of Nieper’s
products when the majority of people trying calcium orotate
as an appetite suppressant can tell almost immediately
that it works, just as Nieper said it would.
Magnesium orotate
Of all the macronutrient
minerals in the human body, magnesium is the one most likely
to be deficient. Magnesium deficiency has been linked to
a large number of disorders, including diabetes 4,
hypertension 5, dementia 6,
and osteoporosis. 7 Magnesium
compounds are medically accepted as helpful for treating
migraines, asthma, chronic lung disease, and cardiac conditions
such as heart attack and arrhythmias. 8 Magnesium
orotate should be even more effective than other magnesium
supplements for such conditions, in view of its enhancement
of magnesium transport and its documented benefits 3, 9, 10 in
cardiovascular disorders.
In addition to
its cholesterol-lowering and heart-energizing effects,
magnesium orotate has also been reported to improve the
elasticity of blood vessels. 11 Using
capillarographic recordings Dr. Nieper was able to show
that a daily dose of 380 mg magnesium orotate over 15 months
was sufficient to normalize or greatly improve the elasticity
of peripheral blood vessels in 60 of 64 patients. Such
an effect on vessel elasticity suggests the use of magnesium
orotate for lowering blood pressure as well as for inhibiting
arteriosclerosis.
Dr. Nieper generally
combined magnesium orotate with other nutrients for optimal
effect. For example, it’s known that potassium deficiency
is closely linked with magnesium deficiency because magnesium
ions are needed to activate an important cellular pump
which regulates sodium and potassium levels. 4, 5 In
addition, potassium orotate itself is thought to be beneficial
for conditions such as cardiomyopathy and congestive heart
failure (see section below on Potassium orotate). So it’s
not surprising to find that Nieper recommended a combination
of magnesium orotate (1.5 to 2.5 grams per day) plus potassium
orotate (138 to 300 mg daily) for treating angina and coronary
heart disease. 12 He also
suggested adding the pineapple enzyme bromelain (120 to
140 mg per day) to inhibit platelet aggregation and dissolve
fibrin clots. The 2- and 4-year mortality rates for patients
on this regimen were reportedly reduced by 90% or more
compared to patients in other studies who received conventional
medications. 12
A similar Nieper
combination designed for unclogging arteries involved magnesium
orotate (1 to 1.5 grams per day) together with carnitine
(4 grams per day), selenium (Se-enriched yeast, 300 to
400 mcg per day), bromelain (240 mg daily), and the enzyme
serrapeptase 10 to 15 mg per day). See my article on CardioPeptase
for additional information.
Finally, it’s
worth pointing out that magnesium orotate isn’t just
for heart patients—it’s also for healthy athletes.
In a double-blind, randomized study, 23 competitive triathletes
were studied after 4 weeks of supplementation with placebo
or magnesium orotate. 13 Blood
was collected before and after a test consisting of a 380-meter
swim, a 20-km bicycle race, and a 5-km run. Compared to
placebo, magnesium orotate caused a greater increase during
the test in serum glucose and venous partial pressure of
oxygen, and a greater decrease in serum insulin, blood
acidity, and serum cortisol. The changes in glucose use
and reduction in stress responses occurred without affecting
the athletes’ competitive potential-quite the reverse,
in fact. The exercising athletes had greater endurance
as a result of the magnesium orotate supplements. By contrast,
a different study in which athletes were supplemented with
magnesium oxide (which is relatively poorly absorbed) reported
no improvement in exercise performance, attesting to the
superior uptake of magnesium in the orotate form compared
to the oxide. 14
Potassium orotate
Potassium deficiency
is not considered to be common in view of the availability
of adequate amounts of this mineral in most diets. Nevertheless,
potassium deficiency is known to arise as a secondary consequence
of magnesium deficiency. 5 Another
cause of deficiency is the use of potassium-wasting diuretics
to control high blood pressure. 15 Disease
states known to be associated with low serum or tissue
potassium include diabetes 4,
insulin resistance 16, and
high blood pressure 5, 17 as
well as rheumatoid arthritis18 and heart disease. 18
Dr. Nieper’s
original motivation to develop orotic acid as an electrolyte
carrier was inspired by results due to E. Bajusz showing
that potassium orotate can prevent idiopathic myocardial
necrosis in hamsters, while potassium chloride is ineffective. 19, 20 Nieper
subsequently found that potassium orotate was highly effective
for alleviating human cardiovascular diseases when combined
with magnesium orotate (see discussion in the section below
on Magnesium orotate). Even when administered by itself
to heart attack patients, potassium orotate has been reported
to result in faster recovery of myocardial contractibility
than in placebo-treated controls. 21
Other reported
applications for potassium orotate include acceleration
of wound healing 22 and
enhancement of recovery and immune function following surgery. 23 Although
not an antioxidant itself, potassium orotate facilitates
the tissue uptake of vitamin C from serum and increases
blood levels of reduced glutathione. 24 Finally,
studies in animals have revealed antidepressant, psychostimulant,
and anxiety-reducing effects associated with chronic potassium
orotate administration. 25, 26
Lithium orotate
Although no absolute
need for lithium has yet been established in human nutrition,
lithium intake can affect many different systems in the
body in a positive way. Lithium is most famous for treatment
of manic-depressive disorders. At high doses lithium can
depress dopamine release 27 (which
tends to flatten elevated moods), while at lower doses
it can stimulate serotonin synthesis 28 (which
gives an antidepressant effect). Although most people don’t
need treatment for manic-depressive illness, a very large
number with mild depression could benefit from low-dose
lithium supplements. Recently it’s been discovered
that lithium has potent neuroprotective effects as well
(see the article Lithium increases gray matter in the brain).
The hope now is that lithium supplements will prove capable
of halting the progress of neurodegenerative diseases such
as Alzheimer’s, Parkinson’s, and amyotrophic
lateral sclerosis, among others.
Lithium is also
known for its immune-enhancing and antiviral effects, especially
against herpes simplex virus. 29 It
may be equally effective against measles, judging by results
obtained in vitro. 30 The
downside to lithium’s immune-stimulating activity
is that it can also set off autoimmune reactions in susceptible
individuals. 31 For
this reason, if you suffer from an existing autoimmune
disease such as rheumatoid arthritis or lupus, don’t
take lithium supplements without first consulting your
health care professional.
Another benefit
of supplementing with lithium is its insulin-sensitizing
effect. 32 Lithium
has been found to decrease blood glucose levels, especially
when used in conjunction with insulin or oral glucose-lowering
drugs. 33 Results
such as these have led to suggestions that lithium might
be useful in treating diabetes. 32, 33
As expected in
view of the neurological activity of lithium compounds,
Dr. Nieper found that lithium orotate in doses of 138 mg
4 to 6 times per week was effective in treating cases of
depression, headaches and migraine, epilepsy, and even
alcoholism. 34 The
amount of lithium contained in the doses was only a small
fraction of the amount conventionally given as therapy
for manic-depressive illness, thus avoiding the risk of
kidney toxicity typically associated with high-dose lithium.
Elsewhere Dr. Nieper reported that 5 mg of lithium in the
form of orotate was roughly as effective as 100 mg of lithium
in the form of carbonate, giving a 20-fold enhancement
of potency thanks to efficient transport of the lithium
by its orotate carrier. 35
Nieper’s
results were subsequently confirmed in a group of 42 alcoholic
patients who were followed for between 6 months and 10
years. 36 Treatment with 138
mg of lithium orotate per day resulted not only in a marked
decline in alcoholic relapses, but also in improvements
in liver, cardiovascular, thyroid, and immune function.
Migraines, cluster headaches, manic behavior, and seizure
disorders were also reduced among this group. Eight patients
reportedly developed muscle weakness, loss of appetite,
and mild apathy as a result of treatment, but symptoms
disappeared after the dose was reduced to 138 mg 4 to 5
times per week. The improvements in liver function appeared
to be due to a synergy between lithium orotate and calcium
orotate, both of which were administered to the alcoholic
patients with liver disease. For more information on the
treatment of liver disorders with a combination of lithium
and calcium orotate, see the section below on Calcium orotate.
Note on lithium safety
As mentioned above,
lithium in large doses can be toxic, especially to the
kidneys. The therapeutic dose of lithium when administered
as lithium carbonate is close to the toxic dose (i.e.,
there is a narrow therapeutic window), and for this reason
blood levels and organ function need to be monitored continually.
This is true only for lithium carbonate and not for lithium
orotate. For example, according to the Physicians’ Desk
Reference, the recommended dose of lithium carbonate administered
for treatment of psychiatric disorders is 300 mg three
to four times per day. Since each 300 mg tablet of lithium
carbonate provides 56.8 mg of elemental lithium, the total
amount of lithium delivered would range from 170.4 mg to
225.6 mg per day. By contrast one lithium orotate tablet
delivers 5.8 mg elemental lithium, which is roughly 1/30
to 1/40 the amount delivered by the recommended daily dose
of lithium carbonate. Even taking several lithium orotate
tablets per day would amount to a dose well below the toxic
level for lithium.
Similarly, consumers
of lithium carbonate are often warned of possible toxic
effects if other medications such as ACE inhibitors or
diuretics are taken concurrently. Although these warnings
appear to be true for pharmaceutical lithium compounds
only and not for modest doses of lithium orotate, it would
nevertheless be wise to consult with a health care professional
for anyone contemplating taking lithium orotate concurrently
with either of these medications.
Zinc orotate
Zinc deficiency
has been implicated in age-related osteoporosis 37 and,
conversely, zinc supplements can speed the healing of fractures
in animal models. 38 Zinc
also plays a vital role in immune function, where deficiency
is associated with atrophy of the thymus, reduction in
white blood cell counts, and increased susceptibility to
infection. 39, 40 Another
important role for zinc is in maintaining male reproductive
function. Deficiency of zinc is associated with hypogonadism
and low levels of serum testosterone, reversible upon supplementation. 41 Zinc
also appears to be important for the activity of growth
hormone (GH) since GH loses effectiveness under conditions
of zinc deficiency. 42
As is well known,
one of the major roles for zinc in human nutrition is its
antioxidant activity. 43 Increasing
zinc intake may protect against conditions associated with
both oxidant stress and zinc deficiency, such as diabetes. 44 Zinc
deficiency is known to be associated with an increased
prevalence of coronary artery disease as well as diabetes,
and with several associated risk factors including hypertension,
hypertriglyceridemia, and insulin resistance (syndrome
X). 45, 46
In view of the
association of zinc deficiency with diabetes, it’s
not surprising to learn that zinc orotate stabilizes blood
glucose and reduces the need for insulin in diabetics,
according to Dr. Nieper. 35 In
addition, zinc orotate and other zinc compounds synergize
with sulfur-containing antioxidants (sulfhydryls) to protect
against free radical-induced tissue injury 43, 47,
a result which may have relevance to the treatment of diabetes
as well as other diseases of increased oxidative stress. 44
Calcium orotate
Treatment or prevention
of osteoporosis is one of the main applications for calcium
supplements generally and for calcium orotate in particular.
Dr. Nieper specifically cited its effectiveness in treating
both inflammatory and osteoporotic decalcification and
in relieving pain resulting from osteoporosis of the spine. 19 In
another paper Nieper reported successful recalcification
of malignant bone tumors (thereby preventing further metastases)
with calcium orotate in 10 out of 13 subjects. 1 He
also found that a daily oral dose of about 600 mg was sufficient
to reverse bone loss caused by radiological therapy in
cancer patients, an effect documented by X-ray photos of
several subjects before and after treatment with calcium
orotate. 1, 19 A
further paper reported on the benefits of calcium orotate
in treating joint diseases such as arthritis and spondylitis. 48 On
the basis of results such as these, it seems likely that
calcium orotate can also have a beneficial impact on the
degenerative bone changes characteristic of osteoarthritis.
(For information on an orotate formulation optimized for
bone health, see description below of Osteo Forte Orotate.)
But calcium orotate
has many other uses as well. In his remarkable paper of
1969 Dr. Nieper reported his observations after dispensing
more than 38,000 doses of calcium orotate to a large number
of patients over the course of a year. 19 Nieper
found that low-dose calcium orotate was effective in treating
severe refractory psoriasis, lowering blood pressure in
cases of arteritis and arteriosclerosis, relieving angina
pectoris, and ameliorating cases of multiple sclerosis,
disseminated encephalitis, retinitis, chronic hepatitis,
and colitis. The dosages employed varied from about 300
to 1000 mg calcium orotate per day. No side effects were
noted except for a loss of appetite among obese chronic
overeaters, some of whom were able to lose a substantial
amount of excess weight.
In subsequent research
Nieper reported achieving complete remissions of chronic,
aggressive hepatitis in 14 patients treated with 3 grams
of calcium orotate per day for 2 years; 4 of these patients
also required cortisone therapy, although at a decreased
dosage. 49 Nieper
found that an optimal therapeutic effect was achieved after
a period of 9 to 18 months of daily supplementation, but
not earlier. However, with a regimen of 2 grams calcium
orotate plus 138 mg lithium orotate per day, the same beneficial
results could be achieved in cases of hepatitis and cirrhosis
in only 2 to 3 months. This research should be re-investigated
in view of the emerging global health crisis of hepatitis
C.
Around 1975 Dr.
Nieper began treating lupus erythematosus patients with
calcium orotate. 35 He found that a dose of 1 to 2.5 grams
was surprisingly effective when administered over a period
of at least one year, even in advanced cases with pulmonary
constriction, pleural effusions, or cardiomyopathy. 35, 50 Therapy
also involved low-dose prednisone and a variety of nutrients
to promote adrenal steroid synthesis, such as selenium
and vitamins C and D2, as well as other calcium and magnesium
salts. An account of one patient’s successful response
to therapy with calcium orotate and other Nieper compounds
can be found in an article available from the Brewer Science
Library. 51 In
addition Nieper found that multiple sclerosis sometimes
accompanies lupus, so it’s not surprising that his
protocol for treating MS is strikingly similar to that
for treating lupus. 52, 53 He
recommended a dose of 1 gram calcium orotate per day for
MS patients, with a higher dose given to those patients
with a tendency toward migraine-like headaches.
Osteo Forte orotate
The benefits of
calcium orotate for healthy bone metabolism can be amplified
by adding a variety of other minerals. Magnesium 7,
manganese 54, zinc 36,
and boron 55 are all known
to act in concert with vitamin D and calcium. Osteo Forte
Orotate combines calcium, zinc, and magnesium orotates
with other nutrients in a synergistic formulation optimal
for maintaining bone health.
References
-
Nieper HA.
Recalcification of bone metastases by calcium diorotate.
Agressologie. 1970;11(6):495-502. Available as article
#CA21 from the A. Keith Brewer International Science
Library at (608) 647-6513 or http://www.mwt.net/~drbrewer/cancer.htm#Professional
-
Nieper HA.
The clinical applications of lithium orotate. A two
years study. Agressologie. 1973;14(6):407-11. Available
as article #CM12 from the A. Keith Brewer International
Science Library at (608) 647-6513 or http://www.mwt.net/~drbrewer/cancer.htm#Professional
-
Rosenfeldt
FL. Metabolic supplementation with orotic acid and
magnesium orotate. Cardiovasc Drugs Ther. 1998;12(Suppl
2):147-52. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Durlach J,
Collery P. Magnesium and potassium in diabetes and
carbohydrate metabolism. Review of the present status
and recent results. Magnesium. 1984;3(4-6):315-323.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Altura BM,
Altura BT. Interactions of Mg and K on blood vessels—aspects
in view of hypertension. Review of present status and
new findings. Magnesium. 1984;3(4-6):175-94.
-
Glick JL.
Dementias: the role of magnesium deficiency and an
hypothesis concerning the pathogenesis of Alzheimer's
disease. Med Hypotheses. 1990;31:211-225. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Rude RK,
Kirchen ME, Gruber HE, Meyer MH, Luck JS, Crawford
DL. Magnesium deficiency-induced osteoporosis in the
rat: uncoupling of bone formation and bone resorption.
Magnes Res. 1999;12(4):257-67. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Swain R,
Kaplan-Machlis B. Magnesium for the next millennium.
South Med J. 1999;92(11):1040-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Villanyi
P, Votin J, Rahlfs V. Arteriosclerosis, myocardial
infarct and blood lipids, their therapeutic modification
by magnesium orotate [in German]. Wien Med Wochenschr.
1970;120(5):76-83.
-
Jellinek
H, Takacs E. Morphological aspects of the effects of
orotic acid and magnesium orotate on hypercholesterolaemia
in rabbits. Arzneimittelforschung. 1995;45(8):836-42.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Nieper HA.
Capillarographic criteria on the effect of magnesium
orotate, EPL substances and clofibrate on the elasticity
of blood vessels. Agressologie. 1974;15(1):73-7. Available
as article #CM19 from the A. Keith Brewer International
Science Library at (608) 647-6513 or http://www.mwt.net/~drbrewer/cancer.htm#Professional
-
Nieper HA.
Lowering of incidence of infarction by means of magnesium
orotate and potassium orotate in combination with bromelain
[in German; unpublished ms., 1977]. Cited in: Heart
disease treated with orotates and bromelain. Available
as article #CM17 from the A. Keith Brewer International
Science Library at (608) 647-6513 or http://www.mwt.net/~drbrewer/cancer.htm#Professional
-
Golf SW,
Bender S, Gruttner J. On the significance of magnesium
in extreme physical stress. Cardiovasc Drugs Ther.
1998;12(Suppl 2):197-202. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Weller E,
Bachert P, Meinck HM, Friedmann B, Bartsch P, Mairbaurl
H. Lack of effect of oral Mg-supplementation on Mg
in serum, blood cells, and calf muscle. Med Sci Sports
Exerc. 1998;30(11):1584-91. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Franse LV,
Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate
WB. Hypokalemia associated with diuretic use and cardiovascular
events in the Systolic Hypertension in the Elderly
Program. Hypertension. 2000;35(5):1025-30. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
[Full text] [PDF (110 KB)]
-
Norbiato
G, Bevilacqua M, Meroni R, et al. Effects of potassium
supplementation on insulin binding and insulin action
in human obesity: protein-modified fast and refeeding.
Eur J Clin Invest. 1984;14(6):414-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Rubenowitz
E, Landin K, Wilhelmsen L. Skeletal muscle magnesium
and potassium by gender and hypertensive status. Scand
J Clin Lab Invest. 1998;58(1):47-54. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Weber CE.
Potassium in the etiology of rheumatoid arthritis and
heart infarction. J Appl Nutr. 1974;26(1-2):41-67.
-
Nieper HA.
The anti-inflammatory and immune-inhibiting effects
of calcium orotate on bradytrophic tissues. Agressologie.
1969;10(4):349-57. Available as article #CM14 from
the A. Keith Brewer International Science Library at
(608) 647-6513 or http://www.mwt.net/~drbrewer/cancer.htm#Professional
-
Bajusz E.
Interrelationships between reparative processes in
myocardium and the development of congestive heart
failure. Rev Can Biol. 1968;27(1):45-60.
-
Tomov L,
Kaloianova A. Changes in hemodynamics in acute myocardial
infarct following administration of potassium orotate
[in Bulgarian]. Vutr Boles. 1976;15(4):79-82. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Kolokol'chikova
EG, Pal'tsyn AA. Electron-radioautographic study of
the effect of potassium orotate on RNA and protein
synthesis in fibroblasts during experimental wound
healing [in Russian]. Biull Eksp Biol Med. 1983;96(8):115-8.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Bilich GL,
Nazarova LV, Sungurova EV. The enzymatic status of
circulating lymphocytes as an index of the regenerative
process in the lungs under stimulation with pyrimidine
and purine derivatives. A clinical experimental study.
Haematologia (Budap). 1982;15(1):71-81. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Kuzdenbaeva
RS, Kurakina VE, Iztleuov MK. Effect of anabolic substances
on the state of the individual components of the glutathione-ascorbic
acid system [in Russian]. Farmakol Toksikol. 1980;43(5):607-9.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Karkishchenko
NN, Khaitin MI. Comparative study of the indices of
the antidepressive activity of potassium orotate and
piracetam [in Russian]. Farmakol Toksikol. 1985;48(2):32-5.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Karkishchenko
NN, Khaitin MI. Quantitative evaluation of the anxiolytic
and nootropic effects of potassium orotate in a wide
range of doses [in Russian]. Farmakol Toksikol. 1986;49(1):14-6.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Dziedzicka-Wasylewska
M, Mackowiak M, Fijat K, Wedzony K. Adaptive changes
in the rat dopaminergic transmission following repeated
lithium administration. J Neural Transm Gen Sect. 1996;103(7):765-76.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Perez-Cruet
J, Tagliamonte A, Tagliamonte P, Gessa GL. Stimulation
of serotonin synthesis by lithium. J Pharmacol Exp
Ther. 1971;178(2):325-30.
-
Rybakowski
JK. Antiviral and immunomodulatory effect of lithium.
Pharmacopsychiatry. 2000;33(5):159-64. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Cernescu
C, Popescu L, Constantinescu S, Cernescu S. Antiviral
effect of lithium chloride. Virologie. 1988;39(2):93-101.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Lieb J. Lithium
and immune function. Med Hypotheses. 1987;23(1):73-93.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Tabata I,
Schluter J, Gulve EA, Holloszy JO. Lithium increases
susceptibility of muscle glucose transport to stimulation
by various agents. Diabetes. 1994;43(7):903-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Hu M, Wu
H, Chao C. Assisting effects of lithium on hypoglycemic
treatment in patients with diabetes. Biol Trace Elem
Res. 1997;60(1-2):131-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Nieper HA.
The clinical applications of lithium orotate. A two
years study. Agressologie. 1973;14(6):407-11. Available
as article #CM12 from the A. Keith Brewer International
Science Library at (608) 647-6513 or http://www.mwt.net/~drbrewer/cancer.htm#Professional
-
Nieper HA.
Revolution in Technology, Medicine and Society. Oldenburg,
Germany: MIT Verlag; 1985. Available from the A. Keith
Brewer International Science Library at (608) 647-6513
or on the Web.
-
Sartori HE.
Lithium orotate in the treatment of alcoholism and
related conditions. Alcohol. 1986;3(2):97-100. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Atik OS.
Zinc and senile osteoporosis. J Am Geriatr Soc. 1983;31(12):790-1.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Igarashi
A, Yamaguchi M. Increase in bone protein components
with healing rat fractures: enhancement by zinc treatment.
Int J Mol Med. 1999;4(6):615-20. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Mocchegiani
E, Giacconi R, Muzzioli M, Cipriano C. Zinc, infections
and immunosenescence. Mech Ageing Dev. 2000;121(1-3):21-35.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Fraker PJ,
Jardieu P, Cook J. Zinc deficiency and immune function.
Arch Dermatol. 1987;123(12):1699-701. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Prasad AS,
Mantzoros CS, Beck FW, Hess JW, Brewer GJ. Zinc status
and serum testosterone levels of healthy adults. Nutrition.
1996;12(5):344-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Kurtogu S,
Patiroglu TE, Karakas SE. Effect of growth hormone
on epiphyseal growth plates in zinc deficiency. Tokai
J Exp Clin Med. 1987;12(5-6):325-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Powell SR.
The antioxidant properties of zinc. J Nutr. 2000;130(5S
Suppl):1447S-54S. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
[Full text] [PDF (249 KB)]
-
DiSilvestro
RA. Zinc in relation to diabetes and oxidative disease.
J Nutr. 2000;130(5S Suppl):1509S-11S. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
[Full text] [PDF (153 KB)]
-
Singh RB,
Niaz MA, Rastogi SS, Bajaj S, Gaoli Z, Shoumin Z. Current
zinc intake and risk of diabetes and coronary artery
disease and factors associated with insulin resistance
in rural and urban populations of North India. J Am
Coll Nutr. 1998;17(6):564-70. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Falkiewicz
B, Dabrowska E, Lukasiak J, Cajzer D, Jablonska-Kaszewska
I. Zinc deficiency and normal contents of magnesium
and calcium in metabolic X syndrome patients as assessed
by the analysis of hair element concentrations. Biofactors.
2000;11(1-2):139-41.
-
Floersheim
GL. Synergism of organic zinc salts and sulfhydryl
compounds (thiols) in the protection of mice against
acute ethanol toxicity, and protective effects of various
metal salts. Agents Actions. 1987;21(1-2):217-22. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
Nieper HA.
The clinical effect of calcium-diorotate on cartilage
tissue, the specific function dependent upon the pentose
metabolism of bradytrophic tissue [in German]. Z präkt
Geriatrie. 1973;3(4):82-9. English translation available
as article #CM29 from the A. Keith Brewer International
Science Library at (608) 647-6513 or http://www.mwt.net/~drbrewer/cancer.htm#Professional
-
Nieper HA.
Liver orotate: the curative effect of a combination
of calcium-orotate and lithium-orotate on primary and
secondary chronic (aggressive) hepatitis and primary
and secondary liver cirrhosis (lecture, 1974). Available
as article #CM11 from the A. Keith Brewer International
Science Library at (608) 647-6513 or http://www.mwt.net/~drbrewer/cancer.htm#Professional
-
Nieper HA.
Excerpts of comments by Dr. Nieper from various sources,
p. 12 (workshop transcript, 1987). In: Doctor's packet
regarding MS and other illnesses. Available from the
A. Keith Brewer International Science Library at (608)
647-6513 or http://www.mwt.net/~drbrewer/cancer.htm#Professional
-
Pakkala A,
Pakkala L. The muzzled wolf. Total Health. 1982 Sept:47-9.
Available from the A. Keith Brewer International Science
Library at (608) 647-6513.
-
Nieper HA.
Regimen for the treatment of multiple sclerosis (unpublished
ms., updated 1994). Available as article #MS10 from
the A. Keith Brewer International Science Library at
(608) 647-6513 or http://www.mwt.net/~drbrewer/cancer.htm#Professional
-
Nieper HA.
The treatment of multiple sclerosis (unpublished ms.,
1985). Available as article #MS12 from the A. Keith
Brewer International Science Library at (608) 647-6513
or http://www.mwt.net/~drbrewer/cancer.htm#Professional
-
Strause LG,
Hegenauer J, Saltman P, Cone R, Resnick D. Effects
of long-term dietary manganese and copper deficiency
on rat skeleton. J Nutr. 1986;116(1):135-41. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract
-
McCoy H,
Kenney MA, Montgomery C, Irwin A, Williams L, Orrell
R. Relation of boron to the composition and mechanical
properties of bone. Environ Health Perspect. 1994;102(Suppl
7):49-53. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9794088&dopt=Abstract